Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary ...
Source : https://www.jstage.jst.go.jp/article/ihj/63/4/63_22-052/_article
Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors significantly reduce low-density lipoprotein cholesterol (LDL-C) and improve the prognosis of patients with acute coronary syndrome (ACS). However, the feasibility and safety of early...
Conclusion/Relevance: In patients with extremely high-risk ACS with high levels of LDL-C, adding evolocumab to their treatment regimen as early as possible may enhance lipid lowering, increase the patient's LDL-C compliance rate in the short term, and improve cardiovascular prognosis but will not increase adverse reactions.
...
Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation
Source : https://www.frontiersin.org/articles/10.3389/fmolb.2022.925587/full
Proprotein convertase subtilisin/kexin type 9 (PCSK9), beyond regulating LDL cholesterol (LDL-c) plasma levels, exerts several pleiotropic effects by modulating lipid metabolism in extrahepatic cells such as macrophages. Macrophage cholesterol homeostasis...
Conclusion: PCSK9-i treatment significantly increased HDL-CEC through ABCG1 and aqueous diffusion pathways and reduced the serum CLC in FH patients. The favorable effect of PCSK9-i on functional lipid profile could contribute to the cardiovascular benefit of these drugs in FH patients.
PCSK9 Promotes Endothelial Dysfunction During Sepsis Via the TLR4/MyD88/NF-κB and NLRP3 Pathways - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35930089/
Endothelial dysfunction often accompanies sepsis. We aimed to explore the role of PCSK9 in septic endothelial dysfunction. Sepsis was induced by lipopolysaccharide (LPS) treatment of human umbilical vein endothelial cells...
Relevance: Endothelial dysfunction often accompanies sepsis. We aimed to explore the role of PCSK9 in septic endothelial dysfunction.
Lipid Lowering Therapy: An Era Beyond Statins
Source : https://www.sciencedirect.com/science/article/abs/pii/S0146280622002390?via=ihub
Available online 31 July 2022, 101342 Dyslipidemia, specifically elevated LDL cholesterol levels, causes atherosclerotic cardiovascular disease (ASCVD) and increases the risk of myocardial infarction and stroke. Statins, a class of...
Conclusion/Relevance: Overall, although statins continue to be the gold standard, non-statin therapies are set to play an increasingly important role in managing dyslipidemia.
-
Lipid Management Connect4yrKey Points • Source: Current Problems in Cardiology • Conclusion: “This review explores non-statin lipid-lowering therapies and examines recent advances and emerging research. Over the previous decades, several lipid-lowering therapies, both as monotherapy and Show More
Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial - Cardiovascular Diabetology
Source : https://cardiab.biomedcentral.com/articles/10.1186/s12933-022-01584-8
Background Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve endothelial dysfunction and reduce cardiovascular events in individuals with type 2 diabetes (T2D). Proprotein convertase subtilisin/kexin 9 (PCSK9i) inhibitors reduce cardiovascular events in...
Conclusions: In individuals with T2D, the addition of evolocumab on top of empagliflozin improves endothelial function.
New Therapeutic Approaches in Treatment of Dyslipidaemia-A Narrative Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35890138/
Dyslipidaemia is a well-known risk factor for the development of cardiovascular disease, a leading cause of morbidity and mortality in developed countries. As a consequence, the medical community has been...
Conclusion: This article provides a short summary of new agents currently used or being developed for lipid lowering treatment.
Clinical Aspects of Genetic and Non-Genetic Cardiovascular Risk Factors in Familial Hypercholesterolemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35885941/
1 Division of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary. 2 Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of...
Conclusion: In this review, we summarize the most important genetic and non-genetic factors that might affect the risk prediction and therapeutic strategy in FH through the eyes of clinicians focusing on disorders that might not be in the center of FH research. The review highlights the complexity of FH care and the need of an...
Cardiac rehabilitation performance predicts 1-year major adverse cardiovascular events - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35904222/
doi: 10.1002/clc.23890. Online ahead of print. 1 Internal Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. 2 School of Medicine, University of...
Conclusion: Our proposed CR-score accurately identifies patients at high risk for 1-year MACE following the rehabilitation program. Multicenter validation is required.
Conclusions: SVI varies across the US states and is associated with prevalent cardiovascular comorbidities and ASCVD, independent of age, race and ethnicity, sex, employment, income, and health care coverage. SVI may be a useful assessment tool for health policy makers and health systems researchers examining multilevel influences on...
Pleiotropic Benefits of Statins in Cardiovascular Diseases
Source : https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1873-1978
Drug Res (Stuttg) DOI: 10.1055/a-1873-1978 1 Department of Pharmacology, Faculty of Pharmacy, Integral University, Lucknow, India 1 Department of Pharmacology, Faculty of Pharmacy, Integral University, Lucknow, India 1...
Relevance: This article examines some of the existing molecular explanations underlying statin pleiotropy and discusses if they have clinical relevance in cardiovascular diseases.
Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial
Source : https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00916-3/fulltext
Among patients with ASCVD, moderate-intensity statin with ezetimibe combination therapy was non-inferior to high-intensity statin monotherapy for the 3-year composite outcomes with a higher proportion of patients with LDL cholesterol...
Interpretation: Among patients with ASCVD, moderate-intensity statin with ezetimibe combination therapy was non-inferior to high-intensity statin monotherapy for the 3-year composite outcomes with a higher proportion of patients with LDL cholesterol concentrations of less than 70 mg/dL and lower intolerance-related drug discontinuation or dose...
Evolocumab for prevention of microvascular dysfunction in patients undergoing percutaneous coronary intervention: the randomised, open-label EVOCATION trial
Masaharu Ishihara 1, MD, PhD; Masanori Asakura 1 , 2, MD, PhD; Kiyoshi Hibi 3, MD, PhD; Kozo Okada 3, MD, PhD; Wataru Shimizu 4, MD, PhD; Hitoshi Takano 4,...
Conclusion: In summary, empagliflozin activated Wnt/β-catenin to stimulate FUNDC1-dependent mitochondrial quality surveillance, ultimately improving mitochondrial function and cardiac performance during CRS-3. Thus, empagliflozin could be considered for the clinical management of heart function following acute kidney injury.
Conclusions:...
Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: data mining of the FDA Adverse Event Reporting System - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35818959/
doi: 10.1111/bcp.15460. Online ahead of print. 1 Research Division of Clinical Pharmacology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China. 2 Department of Respiratory, Wuxi No.5 People's...
Conclusion: Data mining of the FAERs is useful for examining PCSK9 inhibitor-induced AEs. Herein, our findings were largely consistent with clinical experience and could help clinicians improve the safety of PCSK9 inhibitors in clinical practice.
Familial Hypercholesterolemia
Source : https://www.ncbi.nlm.nih.gov/books/NBK174884/
Familial hypercholesterolemia (FH) is characterized by significantly elevated low-density lipoprotein cholesterol (LDL-C) that leads to atherosclerotic plaque deposition in the coronary arteries and proximal aorta at an early age and...
Relevance: Familial hypercholesterolemia (FH) is characterized by significantly elevated low-density lipoprotein cholesterol (LDL-C) that leads to atherosclerotic plaque deposition in the coronary arteries and proximal aorta at an early age and increases the risk of premature cardiovascular events such as angina and myocardial infarction;...
Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35815805/
In this meta-analysis of adverse event data from the large randomised trials of statins, approaches based on common standards for data organisation and classification have provided a resource capable of...
Conclusion: In this meta-analysis of adverse event data from the large randomised trials of statins, approaches based on common standards for data organisation and classification have provided a resource capable of allowing reliable and rapid evaluation of any previously unknown benefits or hazards of statin therapy.
Regulatory Non-Coding RNAs in Familial Hypercholesterolemia, Theranostic Applications
Source : https://www.frontiersin.org/articles/10.3389/fcell.2022.894800/full
Familial hypercholesterolemia (FH) is a common monogenic disease which is associated with high serum levels of low-density lipoprotein cholesterol (LDL-C) and leads to atherosclerosis and cardiovascular disease (CVD). Early diagnosis...
Relevance: In this review, we briefly discussed the mechanisms and pathophysiology of FH and novel therapeutic strategies for the treatment of FH. Moreover, the theranostic effects of different non-coding RNAs for the treatment and diagnosis of FH were highlighted. Finally, the advantages and disadvantages of ncRNA-based therapies vs....
Retinal Microvascular Changes in Familial Hypercholesterolemia: Analysis with Swept-Source Optical Coherence Tomography Angiography - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35743656/
Familial hypercholesterolemia (FH) is a common but underdiagnosed genetic disorder affecting cholesterol metabolism, leading to atherosclerotic disease. The relationship between retinal microvascular changes and the presence of atheroma in patients...
Relevance: Familial hypercholesterolemia (FH) is a common but underdiagnosed genetic disorder affecting cholesterol metabolism, leading to atherosclerotic disease. The relationship between retinal microvascular changes and the presence of atheroma in patients with FH (FH group), and in comparison to volunteers without FH (CT group), needs...
-
Amy Gonzales4yrInteresting to note that sample population belonging to the FH group are older than those in the control group although the study mentioned that this has no statistical difference. If Show More
Long-term cancer risk in heterozygous familial hypercholesterolemia relatives: a 25-year cohort study - Lipids in Health and Disease
Source : https://lipidworld.biomedcentral.com/articles/10.1186/s12944-022-01666-2
Background Heterozygous familial hypercholesterolemia (HeFH) due to low-density lipoprotein receptor (LDLR) mutations predisposes patients to highly elevated levels of cholesterol, and patients are at increased risk of adverse cardiovascular events...
Conclusion: In Denmark, LDLR mutation-carrying HeFH relatives did not have a different cancer risk than the general population. In contrast, nonmutation-carrying relatives had a lower risk of cancer.
-
Amy Gonzales4yrInteresting study and kudos to the researchers for being able to follow-up patients long-term. Will need more studies and probably see if also applicable in other countries. This study also Show More
-
Lipid Management Connect4yrKey Takeaways • Source: Lipids in Health and Disease • Conclusion: “In Denmark, LDLR mutation-carrying HeFH relatives did not have a different cancer risk than the general population. In contrast, nonmutation-carrying relatives had a Show More
absolute cardiovascular benefits of PCSK9 inhibitors and ezetimibe added to maximally tolerated statin therapy depend on individual baseline cardiovascular risk
Source : https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehac360/6631405?login=false
Comment on the article 'PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-an
Relevance: This systematic review and network meta-analysis of randomized controlled trials compared the impact of ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9-i) on cardiovascular (CV) outcomes in patients taking maximally tolerated statin therapy or who were statin-intolerant.
-
Amy Gonzales4yrIn patents with high to very high-risk cardiovascular risk who are on maximal dose of statin that is tolerated, adding ezetimibe and PCS9-i is recommended to achieve beneficial effects.
Modifiable potential risk factors in familial and sporadic frontotemporal dementia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35767471/
doi: 10.1002/acn3.51619. Online ahead of print. 1 Institute of Clinical Medicine - Neurology, University of Eastern Finland, Kuopio, Finland. 2 Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences,...
Interpretation: Our study suggests distinct profiles of several modifiable factors in the FTD group depending on the phenotype and familial inheritance history and that especially sporadic FTD may be associated with modifiable risk factors.